Teladoc Health Inc. [TDOC] stock is up 1.41 while the S&P 500 has fallen -1.17% on Wednesday, 11/18/20. While at the time of this article, TDOC ATR is sitting at 10.65, with the beta value at 0.35. This stock’s volatility for the past week remained at 4.09%, while it was 5.30% for the past 30-day period. TDOC has risen $2.53 from the previous closing price of $179.34 on volume of 4.24 million shares.
On 5, November 2020, Teladoc Health to Participate in Upcoming Investor Conferences. According to news published on Yahoo Finance, Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that executives from the company will participate in the following upcoming investor conferences:.
Analyst Birdseye View:
The most recent analyst activity for Teladoc Health Inc. [NYSE:TDOC] stock was on September 22, 2020, when it was Initiated with a Buy rating from DA Davidson, which also raised its 12-month price target on the stock to $250. Before that, on November 13, 2020, Robert W. Baird Recapitulated an Outperform rating and elevated its amount target to $220. On September 02, 2020, Berenberg Upgrade a Buy rating and boosted its price target on this stock to $252. On August 17, 2020, Credit Suisse Upgrade an Outperform rating and increased its price target from $225 to $249. On July 14, 2020, Citigroup Initiated a Buy rating and increased its price target to $275. On July 13, 2020, Argus Initiated a Buy rating and boosted its amount on this stock to $280. On July 07, 2020, Stephens Initiated an Overweight rating and boosted its target amount on this stock to $250. On April 30, 2020, KeyBanc Capital Markets Reiterated an Overweight rating and amplified its amount target to $195.
In the past 52 weeks of trading, this stock has oscillated between a low of $75.20 and a peak of $253.00. Right now, according to Wall Street analyst the average 12-month amount target is $247.20. At the most recent market close, shares of Teladoc Health Inc. [NYSE:TDOC] were valued at $181.87. According to the average price forecast, investors can expect a potential return of 1.9%.
Teladoc Health Inc. [NYSE:TDOC] most recently reported quarterly sales of 288.81 billion, which represented growth of 109.30%. This publicly-traded organization’s revenue is $230,545 per employee, while its income is -$41,193 per employee. This company’s Gross Margin is currently 62.70%, its Operating Margin is -8.40%, its Pretax Margin is -19.78, and its Net Margin is -17.87. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -6.36, -9.75, -4.61 and -6.80 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 31.69 and the whole liability to whole assets at 28.13. It shows enduring liability to the whole principal at 31.35 and enduring liability to assets at 0.28 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 177.82 points at 1st support level, the second support level is making up to 173.77. But as of 1st resistance point, this stock is sitting at 185.40 and at 188.93 for 2nd resistance point.
Teladoc Health Inc. [TDOC] reported its earnings at -$0.43 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.32/share signifying the difference of -0.11 and -34.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.34 calling estimates for -$0.23/share with the difference of -0.11 depicting the surprise of -47.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Teladoc Health Inc. [NYSE:TDOC] is 6.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.73. Now if looking for a valuation of this stock’s amount to sales ratio it’s 10.87 and it’s amount to book ratio is 6.01.
The most recent insider trade was by Trencher Daniel, SVP Corporate Strategy, and it was the sale of 3000.0 shares on Nov 10. Turitz Andrew, the SVP – Business Development, completed a sale of 1389.0 shares on Nov 04. On Nov 04, Verstraete Stephany, Chief Marketing Officer, completed a sale of 2000.0 shares.